Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population
CPT: Pharmacometrics & Systems Pharmacology · 2026
DOI: 10.1002/psp4.70344 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Trevor N Johnson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Certara Predictive Technologies, Sheffield, UK. Hauptthemen laut MEDLINE: Drug Development, Models, Biological, Pharmacokinetics. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Physiologically based pharmacokinetic (PBPK) models are increasingly used in pediatric drug development and matching such models to the target population is an important consideration. A US pediatric PBPK model was developed incorporating four sub‐groups describing physiology and enzymatic/transporter levels for White, African American, Hispanic/Latino and Asian subjects. Virtual populations could then be created reflecting the demographics of the clinical study design. Ten different drugs (14 studies) were used to verify the pediatric PBPK model performance. Predicted PK parameters showed reasonable agreement with observed data, 50% of the predicted: observed values were within 0.8–1.25‐fold, 74% within 0.67–1.5‐fold, and 97% within 0.5–2‐fold. There was minimal difference for most drugs in performance between the mixed US and North European pediatric populations. This was partly due to reported studies having low numbers of subjects and under‐representation of some ethnicities. Power calculations showed that to detect a pharmacokinetic difference for the CYP3A4/5 substrates midazolam, sirolimus and tacrolimus between African American and White American children with a power of 80%, 25, 18 and 12 subjects respectively, in each group would be needed. Developing adult and pediatric PBPK models to closely match study populations is important due to their increased regulatory use and with the move to their application in personalized medicine. Such models may also help to bridge some of the ethnic differences not captured in pediatric clinical studies due to the low numbers of subjects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Certara Predictive Technologies, Sheffield, UK.
- Mathematical Sciences, University of Malawi, Zomba, Malawi.
- Division of Population Health, School of Health Sciences, Centre for Biostatistics, University of Manchester, Manchester, UK.
- Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID-Profile: Trevor N Johnson, Joyce van der Heijden, Saskia N de Wildt, Karen Rowland Yeo
Zitieren
APA
Johnson, T. N., Kondowe, F., van der Heijden, J., de Wildt, S. N., Gardner, I., & Yeo, K. R. (2026). Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70344
Vancouver
Johnson TN, Kondowe F, van der Heijden J, de Wildt SN, Gardner I, Yeo KR. Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70344
BibTeX
@article{Johnson2026,
author = {Johnson, Trevor N and Kondowe, Fiskani and van der Heijden, Joyce and de Wildt, Saskia N and Gardner, Iain and Yeo, Karen Rowland},
title = {Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
doi = {10.1002/psp4.70344}
}
EUVIMED